Browsing Tag
Wegovy
37 posts
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
Hims & Hers Health soars over 10% after Wegovy rollout, Q1 strength, and analyst upgrades
Hims & Hers Health stock jumped 10.36% on May 16, 2025, after a Wegovy rollout, strong Q1 earnings, and analyst upgrades boosted investor confidence.
Zepbound outperforms Wegovy in SURMOUNT-5 trial: Eli Lilly’s weight-loss drug achieves 47% greater relative reduction
Zepbound outperforms Wegovy with 20.2% weight loss in SURMOUNT-5 trial. See how Eli Lilly’s stock and investor sentiment responded to this clinical milestone.
Eli Lilly’s oral weight-loss pill shakes Novo Nordisk as investors brace for market shift
Novo Nordisk shares drop after Eli Lilly’s oral weight-loss pill shows promise. Analysts see a shifting obesity drug market. What this means for investors.
Novo Nordisk’s semaglutide 7.2 mg sets new standard in obesity treatment with STEP UP trial results
Novo Nordisk, a leader in chronic disease care, has unveiled compelling results from its STEP UP obesity trial.…
Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors
Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant…
FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction in adults with obesity
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk’s Wegovy, a…